Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal malignancy of the gastrointestinal tract. [1] They represent 1% of malignant tumors of the digestive tract and derive from the interstitial cells of Cajal, which serve as a gut pacemaker by creating the basal electrical rhythm leading to peristalsis. [2] GIST most commonly occur in the stomach (60%-70%), followed by the small intestine (20%-30%) and colorectum (5%-10%); they are also rarely found elsewhere in the abdominal cavity, such as in the mesentery, the omentum, or the retroperitoneum. [3] More than 95% of GISTs express the KIT protein (CD 117), and recently discovered on GIST1 (DOG 1) has also been suggested as a useful diagnostic marker. [4] These two immunohistochemical markers are considered to be the most specific and sensitive markers for GIST. [4] As for the genetic aberrations, approximately, 80% of GISTs have a c-KIT mutation, 8%-10% have mutations in the gene encoding the platelet-derived growth factor receptor alpha (PDGFR-α), and the remaining are wild type for both c-KIT and PDGFR-α genes. [5] The gain-of-function mutations of these genes are critical in the pathogenesis of GIST. The prognosis and genetic features are distinguishable according to the anatomical location; a gastric GIST has a better prognosis and a higher incidence of an exon 11 mutation of c-KIT. [6] Historically, there were limited options for the medical management of GIST, with tumor recurrence frequently observed following complete surgical resection of the primary tumor and a grim prognosis for patients with the unresectable or metastatic disease. However, the introduction of the tyrosine kinase inhibitor (TKI) imatinib mesylate has had a major impact on treatment outcomes for these patients with first-line imatinib 400 mg once a day. On progression to standard-dose imatinib, some patients received either escalated doses of imatinib (600 mg or 800 mg once daily) or sunitinib or regorafenib. Responses to TKI treatment were reported according to the Response Evaluation Criteria in Solid Tumors (1.1). The adverse events were classified based on the Common Terminology Criteria for Adverse Events version 4.0.
Statistical analysis
The duration of PFS was defined by the time from the treatment initiation until the documented disease progression, and overall survival (OS) was calculated from the date of diagnosis until death. The strength of the association between PFS and OS with different prognostic variables (e.g., site of metastases and primary disease site) was investigated by Kaplan-Meier curve and log-rank test. PFS was taken as the primary endpoint for this retrospective analysis, and the secondary endpoints were OS, response to TKI treatment and toxicity profile. All statistical analyses were performed using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Totally, 44 cases of metastatic GIST treated with TKIs were retrospectively reviewed. The baseline patient characteristics were depicted in Table 1 . The main finding on physical examination was a palpable abdominal mass in 36% (n = 16) of cases. In immunohistochemistry, 95% (n = 42) patients expressed positivity for antigen CD117 and 59% (n = 26) cases were positive for CD34.
According to the assessment of response to first-line imatinib therapy, stable disease (SD) was documented in 21 cases (48%), followed by a partial response (PR) in 13 patients (29%). None of our patients achieved a complete response (CR). Median time to response in patients who achieved at least a PR was 4.5 months.
The median PFS was 26 months (95% confidence interval [CI]:
22.8-35.2) for the whole cohort. According to the site of metastases, the median PFS were: 34 months for liver, 26 months for peritoneum, 13 months for lungs, and 23 months for the presence of both liver and peritoneal metastases (P = 0.032) [ Figure 1 ]. Patients with gastric primary had a significantly better PFS in comparison to patients with nongastric primaries, 34 months versus 23 months, respectively (P = 0.012). During the follow-up, there were 20 deaths, showing an estimated median survival of 48 months (95% CI: 28.2-72.4), for the whole cohort. A significant difference in the median survival according to the metastatic sites was also observed. The median survival of patients with liver, peritoneum, lungs, and both liver with peritoneum metastases were 58, 44, 22, and 48 months respectively (P = 0.000) [ Figure 2 ]. Similarly, like PFS, the median survival was also better in patients with gastric primary than that of the patients with nongastric primaries, 53 months versus 44 months, respectively, but that difference was not statistically significant (P = 0.052).
Out of the 25 patients with isolated liver metastases, 8 patients underwent curative intent resection, after a median duration of 7.5 months (range: 4-16 months) imatinib therapy. All of these 8 patients also received adjuvant imatinib. The estimated median survival for this subgroup (n = 8) was 71 months.
First-line imatinib therapy was well-tolerated in our series, and none of our patients developed any serious adverse events requiring treatment interruption. Most common side effects (Grade 1 or 2) were facial hyperpigmentation (n = 17), periorbital edema (n = 16), followed by muscle cramps (n = 7), and diarrhea (n = 4). One patient developed congestive cardiac failure on second-line sunitinib, which improved with conservative measures and therapy was changed to third-line regorafenib for this patient.
Discussions
The treatment of GISTs has represented a dramatic evolution in the concept of the management of advanced/metastatic disease, with a transition from the cytotoxic chemotherapy which offered modest response rates, [10] to the initiation of the molecular targeted therapy, targeting specifically the molecular changes responsible for the pathogenesis of cancer (c-KIT, PDGFR-α). The discovery of STI571 (imatinib mesylate) has revolutionized the treatment of GIST. The encouraging results with the first case studies led to the implementation of Phase I and II trials, showing that imatinib mesylate had significant activity in patients with advanced GIST, achieving PR rate of 53.7%, SD in 27.9%, and toxicity Grade 3 and 4 (bleeding, abdominal pain, and electrolyte disturbances) in 21.1% of cases. [7, 11] Currently, without any doubt, patients with advanced/ metastatic disease should be treated with imatinib according to the algorithms of ESMO and National Comprehensive Cancer Network. [12, 13] The surgical approach to metastatic disease is currently limited to investigational studies in patients with the stable resectable disease or responsive to imatinib therapy. [14, 15] Those who display disease progression after first-line imatinib therapy will only have a surgical indication in very restricted situations. [12, 13] In the second-line setting, one option is to increase the dose of imatinib. Unfortunately, this approach is associated with almost doubling of the Grade 3 and 4 toxicity (63% vs. 43%), significantly higher dose reductions (60% vs. 16%) and greater treatment interruptions (64% vs. 40%). [16, 17] The option of sunitinib therapy for GIST became a reality after its approval in 2006 for the treatment of advanced imatinib-resistant GIST or for imatinib-intolerant patients. [8] For patients with the progressive disease, the decision is based on whether there is limited or extensive systemic disease. Efficacy and safety of sunitinib (37.5 mg/day) versus imatinib (800 mg/day) in this patient population was being evaluated in a Phase IIIb study.
[18] Unfortunately, this was terminated early due to poor recruitment and operational futility. Regorafenib is another TKI with activity against several kinases including KIT, PDGFR, fibroblast growth factor receptor, vascular endothelial cell growth factor receptor-2 (VEGFR2) and 3, TIE-2, and BRAF. In February 2013, the FDA has expanded the approved use of this drug to treat advanced GIST that cannot be surgically removed and no longer respond to imatinib and sunitinib, based on the favorable results of a Phase III trial. [9] The demographic data obtained from our study showed a slight male predominance, which is consistent with the published data, where there is a men: women ratio of 1-1.5:1. [19] [20] [21] In relation with the age at presentation, the reported median age in European series is 66-69 years, [19, 20] and in the SEER database is 63 years. [21] Our results showed a median age, almost one decade lower for the age at the diagnosis, a very relevant figure for the Indian patients. Our findings confirmed the worldwide evidence of liver and peritoneum as the main sites of metastases.
Joensuu et al. documented a prolonged clinical response with times surpassing 24 months in patients of metastatic GIST treated with imatinib. [22] The tumor response rates in metastatic GIST patients, treated with imatinib reported in different studies, showed SD as the main treatment response with ranges of 45%-56%; with CR rates of 2%-5%; and a PR of 20%, which translated into a clinical benefit of 70%-90%, independently of the dose of 400, 600, or 800 mg/day. [7, 11, 17, 22] The results obtained in our series showed a CR rate of 0%, PR of 29%, and SD in 48% of the patients, providing a 77% clinical benefit.
With respect to the median survival, the study with the longest follow-up (71 months), published by Blanke et al., reported a median survival of 57 months, independently of the imatinib dose. [23] The current series showed an inferior survival, with an estimated median of 48 months. This difference might be influenced by the dose modifications of imatinib and regimens used at the time of progression on standard first-line therapy. It is worth mentioning that, most of our patients received an escalated dose of imatinib at the time of progression, and only 5 and 2 patients received sunitinib and regorafenib respectively, as second-and third-line therapy.
There are few published retrospective single center experiences of TKI therapy in advanced/metastatic GIST from India. [24] Shrikhande et al. reported a case series of 29 patients with locally advanced GIST, who were treated with neoadjuvant imatinib before surgery. [25] With a median duration of 8.5 months imatinib therapy, the reported overall response rate was 79.3%. Five patients, initially considered to have locally unresectable lesions, ultimately underwent resection and another 3 patients with metastatic disease, underwent R2 resection (due to the presence of metastasis) with a complete resection of the primary lesion. Nineteen patients, who would have originally required extensive surgery, underwent conservative surgery (R0). The 3-year OS was 100%. Another study on the preoperative use of imatinib in 10 patients with advanced/ metastatic GIST reported 45% median reduction of tumor volume. [26] Six of 10 patients underwent complete resection of the tumor following neoadjuvant imatinib for a median period of 3 months and were disease-free for a median follow-up of 11 months, with no serious toxicity.
Rajappa et al. reported a retrospective series of 50 cases of GIST. [27] Thirty-five patients with advanced disease were treated with imatinib, and CR was noted in 4 (11.8%); 13 (38.2%) each had PR and SD, and 5 (14.8%) had PD. Responses were not different in groups based on sex, site of primary tumor, and number of metastatic sites. In another retrospective analysis of 49 patients with GIST, imatinib was administered after surgery in patients with high-risk, residual or metastatic disease and at the onset of recurrence or metastatic disease in patients with intermediate risk. [28] At a median follow-up of 21 months, 2-and 3-year PFS rates were 61% and 39%, respectively, for all patients. The median PFS in the residual and metastatic group was 10 and 29 months, respectively, although the number of patients was small.
In the present study, we performed subgroup analysis according to the primary disease sites and sites of metastases. The median PFS and OS were significantly better in patients with gastric primary than those of the patients with other primary sites (P < 0.05); and this finding was consistent with the published literature. [6, 29] We also observed a significant decrease in the median PFS and OS in patients with lung metastases versus the hepatic, peritoneal, and other metastatic sites (P < 0.05), establishing pulmonary metastasis as a poor prognostic factor in metastatic GIST.
Conclusions
In the current study, we retrospectively investigated the demographic and clinical features of metastatic GIST cases together with an analysis of potential prognostic factors and their impact on PFS and OS. Imatinib therapy was well-tolerated and induced a sustained clinical benefit in more than half of our patients. Lung metastases seemed to be a poor prognostic factor in patients with metastatic GIST. Further prospective molecular studies are needed to elucidate biological differences and to develop rational strategies for preventing the emergence of resistance to TKI therapy in this patient population.
